We’re excited to be an exhibitor at the BioEscalator Mini Supplier Show on June 9th. This event is specially designed to showcase the latest technologies and laboratory services. Come meet our Biocytogen team to learn about our innovative, humanized mice models and how they’re accelerating antibody drug development.
What is The BioEscalator?
The BioEscalator is the University of Oxford’s bioscience startup incubator. They offer support and resources for high-potential startups looking to enhance human healthcare. It is where science meets business, with collaborations between the University, NHS, researchers, and entrepreneurs.
Event Overview
Date: June 9th, 2026
Venue: BioEscalator, Innovation Building, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK
Event Schedule
For more information about The BioEscalator, please visit their website here.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to connecting with you in Oxford, UK!
